Bad company? The pericardium microbiome in people investigated for tuberculosis

2 pericarditis in an HIV-prevalent setting

- 4 Georgina Nyawo^{1,2†}, Charissa Naidoo^{1,2†}, Benjamin G. Wu^{3,4}, Benjamin Kwok³, Jose C.
- 5 Clemente⁵, Yonghua Li³, Stephanie Minnies¹, Byron Reeve¹, Suventha Moodley^{1,2},
- 6 Thadathilankal-Jess John^{6,7}, Sumanth Karamchand⁷, Shivani Singh³, Alfonso Pecararo⁷,
- 7 Anton Doubell⁷, Charles Kyriakakis⁸, Robin Warren¹, Leopoldo N. Segal³, Grant Theron^{1,2#}
- 8 [†]Contributed equally
- 10 **Running title**: Pericardium microbiome in tuberculosis
- 12 **Affiliations**:

1

3

9

11

- 13 ¹DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African
- 14 Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology
- 15 and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University,
- 16 Cape Town, South Africa;
- 17 ²African Microbiome Institute, Faculty of Medicine and Health Sciences, Stellenbosch
- 18 University, Cape Town, South Africa;
- 19 ³Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New
- 20 York University School of Medicine, New York, USA;
- 21 ⁴Division of Pulmonary and Critical Care, Veterans Affairs New York Harbor Healthcare
- 22 System, New York, NY, USA;
- 23 ⁵Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,
- 24 New York, USA;
- 25 ⁶Panorama Mediclinic, Cape Town, South Africa;
- 26 ⁷Department of Medicine, Division of Cardiology, Stellenbosch University & Tygerberg
- 27 Academic Hospital, Cape Town, South Africa;
- 28 ⁸Life Vincent Pallotti Hospital, Cape Town, South Africa.

29 30 *Corresponding author: 31 Professor Grant Theron, 2nd Floor BMRI Building, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Francie Van Zijl Drive, Tygerberg, South 32 33 Africa, 7505. 34 E-mail: gtheron@sun.ac.za 35 Telephone: +27 21 938 9693 36 37 Keywords: pericarditis, extrapulmonary tuberculosis, microbiome, HIV

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

Abstract Background: The microbiome likely plays a role in tuberculosis (TB) pathogenesis. We evaluated the site-of-disease microbiome and predicted metagenome in people with presumptive tuberculous pericarditis, a major cause of mortality, and explored for the first time, the interaction between its association with C-reactive protein (CRP), a potential diagnostic biomarker and the site-of-disease microbiome in extrapulmonary TB. Methods: People with effusions requiring diagnostic pericardiocentesis (n=139) provided background sampling controls and pericardial fluid (PF) for 16S rRNA gene sequencing analysed using QIIME2 and PICRUSt2. Blood was collected to measure CRP. Results: PF from people with definite (dTB, n=91), probable (pTB, n=25), and non- (nTB, n=23) tuberculous pericarditis differed in β-diversity. dTBs were, vs. nTBs, Mycobacterium-, Lacticigenium-, and Kocuria-enriched. Within dTBs, HIV-positives were Mycobacterium-, Bifidobacterium-, Methylobacterium-, and Leptothrix-enriched vs. HIV-negatives and HIVpositive dTBs on ART were Mycobacterium- and Bifidobacterium-depleted vs. those not on ART. Compared to nTBs, dTBs exhibited short-chain fatty acid (SCFA) and mycobacterial metabolism microbial pathway enrichment. People with additional non-pericardial involvement had differentially PF taxa (e.g., Mycobacterium-enrichment and Streptococcusdepletion associated with pulmonary infiltrates). Mycobacterium reads were in 34% (31/91), 8% (2/25) and 17% (4/23) of dTBs, pTBs, and nTBs, respectively. β-diversity differed between patients with CRP above vs. below the median value (Pseudomonas-depleted). There was no correlation between enriched taxa in dTBs and CRP. Conclusions: PF is compositionally distinct based on TB status, HIV (and ART) status and dTBs are enriched in SCFA-associated taxa. The clinical significance of these findings, including mycobacterial in nTBs pTBs, reads and requires evaluation.

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

Introduction The burden of tuberculosis (TB) is severe in sub-Saharan Africa, where HIV is frequent¹. In 2021, South Africa reported >300 000 incident TB cases and 61 000 deaths¹. About 16% of incident cases are extrapulmonary, affecting sites outside the lungs². Extrapulmonary TB (EPTB) has high fatality, especially in people living with HIV (PLHIV)3. Tuberculous pericarditis (TBP) is an especially severe manifestation, and the deadliest manifestation of EPTB, with up to 40% mortality⁴⁻⁶. Immune responses to Mycobacterium tuberculosis complex (Mtb) involve a cascade of events that are, in part, influenced by the microbiome and their metabolites⁷⁸. For instance, gut enrichment with specific anaerobes (Anaerostipes, Blautia, Erysipelotrichaceae) independently predicts activation of host inflammatory immune pathways and active pulmonary TB compared to sick controls 10. In PLHIV on ART, greater microbially-derived short chain fatty acid (SCFA; butyrate, propionate) concentrations in the lower airways independently predict incident TB¹¹ . When SCFAs are added at physiological concentrations to alveolar macrophages ex vivo, there are reductions in macrophagemediated Mtb kill¹¹. C-reactive protein (CRP) is a non-specific blood inflammatory marker for triage¹², especially in PLHIV in primary care, where it is WHO-recommended¹³. In studies where CRP was coanalysed with the microbiome, CRP negatively correlated with abundances of antiinflammatory-associated gut microbiota 14 such as Faecalibacterium 15, Lactobacillus and Bifidobacterium¹⁶. In COVID-19 patients, CRP correlated with potentially pathogenic bacteria such as Klebsiella spp. and Enterococcus spp. 17 However, the relationship between CRP and the site-of-disease microbiota in presumptive TBP has not been studied. Little is known about the microbiome of the pericardial space, especially in the context of EPTB, a major cause of pericardial disease. Previous research has hinted at the influence of

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

microbiota on TB, making it a promising treatment avenue⁷⁻⁹. Our work showed the presence of distinctive microbial communities at the site of disease in people with presumptive tuberculous lymphadenitis¹⁸. Importantly, these communities differed by TB status (definite-, probable- or non-TB) and clinical characteristics, with specific community states (i.e., Mycobacterium-dominated lymphotype) being associated with more severe disease¹⁸. Together, this can aid in the identification of novel biomarkers at the microbial-host interface that leads to strategies like host-directed therapies for TB prevention and treatment, including in PLHIV. This could also enhance our understanding of severe inflammation in EPTB, which partly contributes to its high morbidity and mortality. Understanding interactions in the microbiome, together with correlations with CRP can help find meaningful networks via which microbes and host interact, and this can help uncover novel associations and mechanisms. We therefore evaluated the site-of-disease microbiome and its predicted metagenome in people investigated for TBP (including PLHIV) as well as whether CRP as a surrogate for inflammation correlates with specific taxa. This work will help provide foundational data on the microbiome's role in TBP.

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

Methods Recruitment and follow-up People with presumed TB pericarditis referred to Tygerberg Academic Hospital in Cape Town, South Africa for routine diagnostic investigation including pericardiocentesis were recruited between 24 November 2016 and 9 April 2021. Eligible people were ≥18 years old and not on TB treatment for ≥2 weeks. Demographic, clinical, and chest X-ray (CXR) data were collected. People with TBP were managed by the overseeing clinician in line with current guidelines for the management and treatment of pericardial effusions, and assessed by telephonic follow-up after a minimum of 12 weeks. The study had no role in patient management. **Ethics** All people provided written informed consent. The study was approved by the Stellenbosch University Health Research and Ethical Committee (HREC, N16/04/050), Tygerberg Academic Hospital, and the Western Cape Department of Health (WC_2016RP15_762). Specimen collection and processing Two sampling controls were collected per person: a skin swab of the sterilised puncture site and a sterile saline (Ysterplaat Medical Supplies, South Africa) flush of the vascular sheath prior to pericardiocentesis (background control). At least 4mL pericardial fluid (PF) was collected once sufficient volumes were obtained for routine diagnostic testing. Samples were stored at -80°C until batched DNA extraction. Peripheral blood was collected in serumseparating tubes (SST tubes; BD), and centrifuged (2054g, 10 min) within four hours of collection, and serum stored at -80°C. Further details on specimen collection and microbiological testing is in the **Supplementary material**. Patient classification

We designated people as definite tuberculous pericarditis (dTB), probable tuberculous pericarditis (pTB), or non-tuberculous pericarditis (nTB) per **Table S1**¹⁹. People were classified as dTBs if they were positive for acid-fast bacilli by Ziehl-Neelsen smear microscopy and/or had at least one MTB-positive specimen by Mycobacteria Growth Indicator Tube (MGIT) 960 liquid culture (BD Diagnostics, USA), Xpert MTB/RIF (Xpert; Cepheid, USA) and/or Xpert MTB/RIF Ultra (Ultra; Cepheid, USA). pTBs did not meet dTB criteria, had no alternative diagnosis, and were empirically prescribed TB therapy. nTBs had no microbiological evidence of TB and were not placed on treatment.

Laboratory procedures

The PureLink Microbiome DNA Purification Kit (Invitrogen, USA) was used for PF, skin swabs and, for efficiency, 1 in 5 background samples. The 16S rRNA gene V4 hypervariable region (150 bp read length, paired-end) was amplified and underwent Illumina MiSeq sequencing¹¹. Further detail is in the **Supplementary Material**. CRP was measured in biobanked serum using the Cobas High-Sensitivity Immunoturbidimetric Assay (Roche Diagnostics Limited, Burgess Hill, UK) per the manufacturer's <u>instructions</u>.

Microbiota analyses

<u>Pre-processing</u>: Sequences were pre-processed using QIIME (version 2020.8)²⁰ and DADA2²¹. Amplicon sequence variants (ASVs) were assigned at 99% similarity against representative sequences in Greengenes (version 13.8)²² with zero abundance taxa removed.

Taxonomic analyses: α- and β-diversities were calculated using *vegan* (v2.6-4)²³. Differential taxa and pathway abundance analyses used *DESeq2* (v1.22.2)²⁴ with Benjamini–Hochberg (BH) multiple testing correction after feature tables were pruned (genera not seen >5 times in ≥1% of samples removed)²⁵. CRP was categorised as high or low if the concentration readout was above or below the median for the people included in that

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

analysis. Detailed methods for identifying potential contaminants and clustering analysis are in the Supplementary Material. Functional pathway analyses: Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt2: v.2.1.3-b)26 was used for metagenomic inference with default parameters (picrust2_pipeline.py) and metabolic function predictions based on MetaCyc²⁷. Correlation analysis with CRP and microbiome: Only sequence data with paired CRP measurements were included. Microbial relative abundances were correlated with CRP measurements using Correlations Under the Influence (CUTIE)²⁸. Statistical analyses Analyses used GraphPad Prism (v7; GraphPad Software, USA), STATA (v16; StataCorp, USA) and R (v4.2; R Core Team). Medians with interquartile ranges (IQRs) were reported for continuous variables, and the number and percentage were reported for categorical variables. Non-parametric tests (microbiome data are not normally distributed²⁹) included the Mann-Whitney or Wilcoxon signed-rank test for unpaired and paired comparisons involving two groups, Kruskal-Wallis or Friedman tests for unpaired and paired comparisons involving ≥2 groups, and Spearman's Rho for correlation analyses. Permutational multivariate analysis of variance (PERMANOVA) was computed with 999 permutations for β -diversity, and R^2 used to measure variation explained by a variable. The Benjamini-Hochberg procedure was used to correct for multiple comparisons by controlling the false discovery rate (FDR)²⁵. Adjusted p-values of <0.2 and <0.05 were considered significant for taxa and pathways. respectively³⁰. More information is in the **Supplementary Methods**.

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

Results Cohort characteristics Our cohort was comprised of 91 (65%), 25 (18%) and 23 (17%) dTBs, pTBs, and nTBs, respectively (Table 1). Compared to nTBs, dTBs were more likely to have HIV, cough, weight loss, be on medication (other than TB medication) and, in their PF, have lower albumin but higher adenosine deaminase (ADA), lactate dehydrogenase (LDH), and unstimulated interferon-gamma (uIFN-y) concentrations. pTBs were more likely than nTBs to have HIV, previous TB, and TB symptoms and, in PF, lower albumin and higher ADA and uIFN-γ concentrations. Pericardial fluid shares few taxa with skin and background controls PF α-diversity was lower than background and skin. PF β-diversity differences occurred with Mycobacterium- (vs. skin and background) and Streptococcus-enrichment (vs. skin only) (Figure S1A-D). None of the top four potentially contaminating taxa identified appeared in differential analyses (Figures S2-3, additional table). Mycobacterium and other potential opportunistic pathogens are enriched in dTBs Differences by TB status: We did not detect α-diversity differences (Figure 2A). βdiversity differed between dTBs and pTBs, as well as pTBs vs. nTBs (PERMANOVA p=0.020 and 0.003, respectively, **Figure 2B**), but not between dTBs and nTBs. dTBs were Mycobacterium-, Lacticigenium-, and Kocuria-enriched vs. nTBs (Figure 2C), and Mycobacterium-, Lacticigenium- and Caulobacter-enriched and Streptococcus-depleted vs. pTBs (Figure 2D). pTBs were Streptococcus- (vs. dTBs) and Novosphingobium-enriched vs. nTBs (Figure 2D-E), and more phylogenetically dissimilar to each other. dTBs were the most phylogenetically similar to each other followed by nTBs (Figure S4). Grouping pTBs with dTBs or nTBs: When pTBs were grouped with dTBs or nTBs, there were no α - or β -diversity differences vs. nTBs or dTBs, respectively (Figure S5A-D).

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

dTBs were Mycobacterium- and Lacticigenium-enriched vs. nTBs regardless of with whom pTBs were grouped (Figure S5E-F). 16S rRNA gene sequencing correlates with diagnostic results: Mycobacterial reads occurred in more dTBs than pTBs [34% (31/91) vs. 8% (2/25), p=0.011] but did not reach significance when dTBs were compared to nTBs [17% (4/23), p=0.181] (Figure 2F, Figure **S6**). Mycobacterial reads inversely correlated with PCR (r=-0.361, p<0.012; **Figure S7A**) and culture measures of mycobacterial load (r=-0.484, p<0.001; Figure S7B). Bifidobacterium enrichment is associated with HIV Although α- and β-diversity did not differ by HIV status (Figure S8A-B), PLHIV were Mycobacterium-enriched vs. HIV-negatives (Figure S8C). Comparisons by HIV status within different TB groups: No α- and β-diversity differences by HIV status occurred in dTBs or pTBs (Table S2). In dTBs, HIV-positives were Methylobacterium-, Bifidobacterium-, and Leptothrix-enriched vs. HIV-negatives (Figure S8D). nTBs were not compared by HIV status due to a small sample size (n=2 HIVpositives). Comparisons by TB status within people of the same HIV status: In HIV-positives, αdiversity was similar by TB status (**Figure 3A**) but β-diversity differed (p=0.038; **Figure 3B**) and dTBs were Mycobacterium-, Bifidobacterium-, and Leptothrix-enriched vs. pTBs (Figure **3C**). α- and β-diversities were similar between HIV-positives with high vs. low CD4 counts (dichotomised at median value, data not shown), where those with lower counts were Mycobacterium-enriched vs. people with higher counts (Figure S9A-B). In HIV-negatives, αand β-diversities were similar between TB groups (Figure 3D-E) and taxonomic differences were only observed between dTBs vs. pTBs, with dTBs Kocuria-, Halomonas-, and Gilvimarinus-enriched (Figure 3F). Comparisons by ART status in PLHIV: A third of PLHIV were on ART (Table 1). α-Diversity was similar by ART status, but β-diversity differed (Table S2). Those on ART were

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

Streptococcus-enriched and Mycobacterium- and Bifidobacterium-depleted vs. those not on ART (Figure S9C) and conclusions were similar when restricted to dTBs (Figure S9D). Chest abnormalities associated with the microbiome. We evaluated microbiome differences by CXR results (Table 1) and found no α-diversity differences. However, β -diversity differed in people with vs. without pulmonary infiltrates (Pls; **Table S2**), with people with Pls *Mycobacterium*-enriched and *Streptococcus*-depleted (Figure 4A). β-diversity also differed in people with or without pleural effusions (PEs) (Table S2), where people with PEs were Streptococcus- and Pseudomonas-enriched and Brachymonas-depleted (Figure 4B). People with definite TBP are enriched in SCFA metabolic pathways. Compared to nTBs, dTBs were enriched with SCFA metabolism (L-lysine fermentation to acetate and butanoate), aromatic compound degradation (cinnamate and hydroxycinnamate degradation to 2-oxopent-4-enoate), and mycobacterial metabolism (superpathway of mycolyl-arabinogalactan-peptidoglycan complex biosynthesis) pathways (Figure 5). Amongst dTBs, HIV-positives were depleted in biosynthesis pathways [GDP-Dglycero-α-D-manno-heptose biosynthesis, peptidoglycan biosynthesis resistance) and superpathway of geranylgeranyl diphosphate biosynthesis II (via MEP)] compared to HIV-negatives (Figure S10). Comparisons involving pTBs are in Figures S11-S12. The association between CRP and the microbiome Microbial composition differed with Pseudomonas depleted in high vs. low CRP CRP concentrations did not differ by TB status [median 137.30 (IQR 75.30 - 176.30) ng/mL in dTBs vs. 95.96 (IQR 45.25 - 173.70) ng/mL in nTBs] (Figure 6A) nor correlated with Mycobacterium reads (Figure 6B-C). People with above median CRP concentrations [median 125.4 (IQR70.83 – 176.7) ng/mL] had, vs. those below the median, no α-diversity

differences (**Figure 6D**) but different β-diversity (**Figure 6E**), with *Pseudomonas*-depletion (**Figure 6F**). These differences were similar when restricted to people of a specific TB (**Table 2**) or HIV status (**Figures S13-14**), with a few additional taxa differentially enriched. The top three taxa enriched in dTBs (*Mycobacterium*, *Lacticigenium*, *Kocuria*) did not correlate with CRP levels (p-values of 0.523, 0.260, and 0.999, respectively).

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

Discussion Our key findings are that 1) compared to PF from people without TBP, PF from people with TBP differs both in terms of β-diversity and the relative abundance of specific taxa, including those other than Mycobacterium (Lacticigenium, Kocuria, and Weeksella), 2) HIV is associated with the differential abundance of Mycobacterium overall, and within dTBs, Bifidobacterium is associated with proxies of more severe disease (HIV-positivity and, in PLHIV, no ART), and 3) taxonomic differences between dTBs and nTBs manifest in different functional capacities, including enrichment of SCFA production pathways. Furthermore, 4) the PF microbiome is associated with distinctive clinical and chest imaging characteristics and 5) many people with dTB do not have PF Mycobacterium reads whereas some people without dTB have Mycobacterium reads, 6) CRP did not differ by TB status or HIV status, and α-diversity was similar by CRP status, however, β-diversity differed, with *Pseudomonas* enrichment in people with low (vs. high) CRP. This is the first characterisations of the site-ofdisease microbiome in people with pericarditis, specifically in a high TB HIV-endemic setting. dTBs were enriched in several taxa in addition to Mycobacterium. These include Kocuria, a skin commensal that causes an infection of the heart e.g., native valve endocarditis, albeit rarely³¹, and Weeksella which can also cause serious bacterial infections like bacteraemia, and spontaneous bacterial peritonitis³². The relevance of these taxa in TBP requires further investigation. Mycobacterium was enriched in PLHIV compared to people without HIV. Furthermore, Bifidobacterium was associated with clinical features characteristic of severe disease (HIVpositivity and, in those with HIV, no ART and lower CD4 counts. Bifidobacterium, while commonly considered a beneficial, immunomodulatory gut commensal³³, has been

described as either depleted ^{9 34} or enriched ^{35 36} in people with pulmonary TB compared to

symptomatic controls. However, our findings are consistent with the latter. Bifidobacterium

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

can act opportunistically, causing bacteraemia in immunocompromised people and those with a damaged intestinal barrier³⁷. Similar to previous work involving people with different forms of TB (i.e., pulmonary TB and TB lymphadenitis³⁸), people with TBP were enriched in SCFA-producing bacteria (e.g., Lacticigenium produces acetic and lactic acid) and pathways (L-lysine fermentation to acetate and butanoate, amino acid and carbohydrate metabolism butyrate precursor pathways)39 40. dTBs also had elevated PF concentrations of LDH, a marker of tissue damage, however we acknowledge that it could include microbially-derived LDH. Lactate metabolism is also important for *Mtb* growth⁴¹ Furthermore, HIV-positive dTBs not on ART are, in addition to Mycobacterium, enriched in Bifidobacterium, a known producer of lactate which itself is also an intermediate metabolite of the butyrate biosynthetic pathway⁴² ⁴³. Butyrate suppresses protective host responses (IFN-y and IL-17A) to Mtb. Future studies should evaluate whether enhanced site-of-disease SCFA production correlates with both local and peripheral inflammation. Pericarditis is often associated with pulmonary parenchymal disease. Notably, the PF microbiome was associated with a greater probability of chest imaging characteristics where individuals with PI showed distinct PF β-diversity compared to those without, characterized by increased Mycobacterium (likely resulting from more direct contact with the route of infection and site of pulmonary disease) and reduced Streptococcus. Similarly, individuals with pleural effusion exhibited different PF β-diversity compared to those without, with higher levels of Streptococcus and lower levels of Brachymonas. Pulmonary infiltrates are commonly observed in radiological imaging of individuals with pulmonary TB⁴⁴, while pleural effusions are predominantly caused by TB in developing countries⁴⁵. Consequently, obtaining sputum cultures and Xpert tests is crucial in suspected cases of TBP, even when parenchymal involvement is not evident. Furthermore, the co-existence of these features

may reflect the TB route from the lungs to the heart, and what taxa might accompany that spread.

People within each TB group had *Mtb* DNA detected. The reasons for this are likely multifaceted: primarily due to technical methodological limitations (metagenomic sequencing would have more discriminatory power for species within *Mycobacteria*) but could also be due to TB exposure, past infection, TB disease at another anatomical site, or crosscontamination. It is important to note that 66% of dTBs did not show *Mycobacterium* readings, likely due to the limited sensitivity of 16S rRNA sequencing for detecting this genus, whose cells often lyse and release DNA inefficiently and may be biased against by conventional sequencing approaches (a "mycobacteriome" approach could be used to study mycobacterial diversity further)⁴⁶.

CRP is a commonly studied biomarker in TB, and during active TB infection, CRP levels tend to be elevated due to the body's immune response to the mycobacterial infection⁴⁷. Similarly, CRP levels can be elevated in individuals with HIV because HIV infection is associated with chronic inflammation and immune activation, particularly in those with advanced disease or opportunistic infections⁴⁸⁻⁵⁰. However, in our study, unlike previously reported studies⁵¹⁻⁵³, the level of CRP, appears to not be influenced by the presence of active TB in TBP. Despite this, the median CRP value in our TBP cohort 125.4 (70.83 – 176.70) ng/mL exceeded the diagnostic threshold ⁵⁴ for TB diagnosis. This observation can be attributed to the fact our study only included people that were suspected to have TPB, leading to the presence of specific clinical symptoms and some form of the disease, regardless of whether it was TB or another condition. As a result, this could have contributed to the elevated CRP levels to some extent. Notably, we observed a depletion of *Pseudomonas* in presumptive TBP people with high CRP compared to those with low CRP, similar to a report of an adverse relationship between sputum genus richness and CRP in bronchiectasis^{55 56}.

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

The study has strengths and limitations. DNA-based sequencing was employed to analyze microbial communities, and alternative methods like culturomics, metagenomics, or metatranscriptomics may yield different results. Furthermore, as our study was nested within TB care at our hospital, our study data were influenced by limitations in routinely available data (e.g., unknown ART duration); however, this allowed us to recruit a high number of people. We also did background sampling and sequencing to detect potential crosscontamination of our low biomass fluid (PF), which allowed us to confirm that none of the discriminatory taxa identified in our analyses likely resulted from contamination. The study used a relaxed FDR-adjusted p-value threshold of 0.2 to identify various taxa, prioritizing hypothesis generation. This threshold was chosen as lower thresholds did not yield significant taxa, underscoring the need for broader exploration. We do not know which microbes are driving the high CRP in TB, however, this study was not designed to investigate this, and further studies would be required. We acknowledge the non-specificity of CRP as a general marker of inflammation. Finally, this study is a cross-sectional study, so it's unable to establish temporal relationships. In summary, the microbiomes of people with TBP (including those co-infected with HIV) are different to people without TBP and characterised by enriched Mycobacterium and other potentially immunomodulatory bacteria (Bifidobacterium, Lacticigenium). Further research is needed to define these mechanistic relationships (e.g., through murine models), including how the microbiota is altered by treatment and its association, if any, with clinical outcomes. This will provide insights into the development of effective host-directed therapies for TBP.

Funding

Trials Partnership (EDCTP; project numbers SF1041, TMA2019CDF-2738-ESKAPE-TB), National Research Foundation, South African Medical Research Council (SAMRC), Harry Crossley Foundation and Stellenbosch University Faculty of Health Sciences. We also acknowledge funding from Veterans Affairs (IK2BX005309-01A2) and the National Institutes of Health under award number KL2TR001446, and CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease. CCN and GT acknowledge funding from the National Institutes of Health under award numbers K43TW012302 and R01Al136894. GRN acknowledges funding from L'Oréal-UNESCO For Women in Science Sub-Saharan Africa Young Talents Award, and the International Rising Talents Award. The content is the solely the responsibility of the authors and does not necessarily represent the official views of the funders.

Acknowledgments

- The authors thank all study participants and CLIME staff, especially Sr Ruth Wilson.
- 394 Computations were performed using facilities provided by the University of Cape Town's
- 395 ICTS High Performance Computing team: <u>hpc.uct.ac.za.</u>

Conflict of Interest

The other authors each declare no competing interests.

References

- 401 1. World Health Organization. Global Tuberculosis Report 2022. Geneva, Switzerland, 2022.
- 402 2. Gupta RK, Lawn SD, Bekker L-G, et al. Impact of human immunodeficiency virus and
- 403 CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South
- 404 Africa. The international journal of tuberculosis and lung disease 2013;17(8):1014-22.

- 405 3. Leeds IL, Magee MJ, Kurbatova EV, et al. Site of extrapulmonary tuberculosis is
- 406 associated with HIV infection. 2012;55(1):75-81.
- 407 4. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation
- 408 2005;112(23):3608-16.
- 409 5. Noubiap JJ, Agbor VN, Ndoadoumgue AL, et al. Epidemiology of pericardial diseases in
- 410 Africa: a systematic scoping review. *Heart* 2019;105(3):180-88.
- 411 6. Mayosi BM, Wiysonge CS, Ntsekhe M, et al. Mortality in patients treated for tuberculous
- 412 pericarditis in sub-Saharan Africa. S Afr Med J 2008;98(1):36-40.
- 413 7. Somboro AM, Diallo D, Holl JL, Maiga M. The role of the microbiome in inflammation
- 414 during tuberculosis. EBioMedicine 2021;68
- 8. Mori G, Morrison M, Blumenthal A. Microbiome-immune interactions in tuberculosis. *PLoS*
- 416 Pathogens 2021;17(4):e1009377.
- 417 9. Naidoo CC, Nyawo GR, Sulaiman I, et al. Anaerobe-enriched gut microbiota predicts pro-
- inflammatory responses in pulmonary tuberculosis. *EBioMedicine* 2021;67:103374.
- 419 10. Naidoo CC, Nyawo GR, Wu BG, et al. The microbiome and tuberculosis: state of the art,
- 420 potential applications, and defining the clinical research agenda. Lancet Respir Med
- 421 2019;7(10):892-906. doi: 10.1016/S2213-2600(18)30501-0 [published Online First:
- 422 20190322]
- 423 11. Segal LN, Clemente JC, Li Y, et al. Anaerobic Bacterial Fermentation Products Increase
- 424 Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients. Cell host & microbe
- 425 2017;21(4):530-37 e4. doi: 10.1016/j.chom.2017.03.003
- 426 12. Du Clos TW. Function of C-reactive protein. *Annals of medicine* 2000;32(4):274-78.
- 427 13. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2:
- 428 screening-systematic screening for tuberculosis disease. Geneva, Switzerland: World
- 429 Health Organization 2021.
- 430 14. Ma W, Nguyen LH, Song M, et al. Dietary fiber intake, the gut microbiome, and chronic
- 431 systemic inflammation in a cohort of adult men. *Genome medicine* 2021;13(1):102.

- 432 15. Furet J-P, Kong L-C, Tap J, et al. Differential adaptation of human gut microbiota to
- 433 bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation
- 434 markers. *Diabetes* 2010;59(12):3049-57.
- 435 16. Rajkumar H, Mahmood N, Kumar M, et al. Effect of probiotic (VSL# 3) and omega-3 on
- 436 lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight
- adults: a randomized, controlled trial. *Mediators Inflamm* 2014;2014
- 438 17. Petakh P, Kobyliak N, Kamyshnyi A. Gut microbiota in patients with COVID-19 and type
- 439 2 diabetes: A culture-based method. Frontiers in Cellular and Infection Microbiology
- 440 2023;13:108.
- 441 18. Nyawo GR, Naidoo CC, Wu B, et al. More than Mycobacterium tuberculosis: site-of-
- 442 disease microbial communities, and their functional and clinical profiles in tuberculous
- 443 lymphadenitis. *Thorax* 2023;78(3):297-308.
- 444 19. Reuter H, Burgess L, van Vuuren W, Doubell A. Diagnosing tuberculous pericarditis.
- 445 QJM: An International Journal of Medicine 2006;99(12):827-39. doi:
- 446 10.1093/qjmed/hcl123
- 447 20. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible
- 448 microbiome data science using QIIME 2. *Nature biotechnology* 2019;37(8):852-57.
- 21. Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: high-resolution sample inference
- 450 from Illumina amplicon data. *Nature methods* 2016;13(7):581-83.
- 451 22. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with
- explicit ranks for ecological and evolutionary analyses of bacteria and archaea. The ISME
- 453 *journal* 2012;6(3):610.
- 454 23. Dixon P. VEGAN, a package of R functions for community ecology. Journal of
- 455 Vegetation Science 2003;14(6):927-30.
- 456 24. McMurdie PJ, Holmes S. Waste not, want not: why rarefying microbiome data is
- inadmissible. *PLoS computational biology* 2014;10(4)
- 458 25. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false
- discovery rate controlling procedures. *Bioinformatics* 2003;19(3):368-75.

- 460 26. Douglas GM, Maffei VJ, Zaneveld J, et al. PICRUSt2: An improved and customizable
- approach for metagenome inference. *BioRxiv* 2020:672295.
- 462 27. Caspi R, Altman T, Billington R, et al. The MetaCyc database of metabolic pathways and
- 463 enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res
- 464 2014;42(D1):D459-D71.
- 465 28. Bu K, Wallach DS, Wilson Z, et al. Identifying correlations driven by influential
- observations in large datasets. *Briefings in Bioinformatics* 2022;23(1):bbab482.
- 467 29. Estaki M, Jiang L, Bokulich NA, et al. QIIME 2 Enables Comprehensive End-to-End
- 468 Analysis of Diverse Microbiome Data and Comparative Studies with Publicly Available
- Data. Current protocols in bioinformatics 2020;70(1):e100.
- 470 30. Seumois G, Zapardiel-Gonzalo J, White B, et al. Transcriptional profiling of Th2 cells
- 471 identifies pathogenic features associated with asthma. The Journal of Immunology
- 472 2016;197(2):655-64.
- 473 31. Kandi V, Palange P, Vaish R, et al. Emerging bacterial infection: identification and
- draw clinical significance of Kocuria species. *Cureus* 2016;8(8)
- 475 32. Campbell IM, Congdon M, Capucilli PS, Fox WW. A Not So Common Infection in an
- 476 Extremely Low-Birth-Weight Infant. Clinical Pediatrics 2020;59(11):1040-42.
- 477 33. Lokesh D, Parkesh R, Kammara R. Bifidobacterium adolescentis is intrinsically resistant
- 478 to antitubercular drugs. *Scientific reports* 2018;8(1):11897.
- 479 34. Baral T, Kurian SJ, Thomas L, et al. Impact of tuberculosis disease on human gut
- 480 microbiota: a systematic review. Expert Review of Anti-infective Therapy 2023(just-
- 481 accepted)
- 482 35. Khaliq A, Ravindran R, Afzal S, et al. Gut microbiome dysbiosis and correlation with
- 483 blood biomarkers in active-tuberculosis in endemic setting. PloS one
- 484 2021;16(1):e0245534.
- 485 36. Wang Y, Deng Y, Liu N, et al. Alterations in the Gut Microbiome of Individuals With
- 486 Tuberculosis of Different Disease States. Frontiers in Cellular and Infection Microbiology
- 487 2022:328.

- 488 37. Esaiassen E, Hjerde E, Cavanagh JP, et al. Bifidobacterium bacteremia: clinical
- 489 characteristics and a genomic approach to assess pathogenicity. Journal of clinical
- 490 *microbiology* 2017;55(7):2234-48.
- 491 38. Nyawo GG, Naidoo CC, Wu B, et al. More than Mycobacterium tuberculosis: specific
- 492 site-of-disease microbial communities, functional capacities, and their distinct clinical
- 493 profiles in tuberculous lymphadenitis. *bioRxiv* 2022
- 494 39. Schillinger U, Endo A. Minor genera of the Carnobacteriaceae: Allofustis, Alloiococcus,
- 495 Atopobacter, Atopococcus, Atopostipes, Bavariicoccus, Desemzia, Dolosigranulum,
- 496 Granulicatella, Isobaculum and Lacticigenium. Lactic Acid Bacteria: Biodiversity and
- 497 *Taxonomy* 2014:159-70.
- 498 40. lino T, Suzuki K-i, Harayama S. Lacticigenium naphtae gen. nov., sp. nov., a halotolerant
- and motile lactic acid bacterium isolated from crude oil. *International journal of systematic*
- and evolutionary microbiology 2009;59(4):775-80.
- 501 41. Billig S, Schneefeld M, Huber C, et al. Lactate oxidation facilitates growth of
- Mycobacterium tuberculosis in human macrophages. *Scientific reports* 2017;7(1):1-12.
- 503 42. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host
- 504 physiology: short-chain fatty acids as key bacterial metabolites. Cell 2016;165(6):1332-
- 505 45.
- 506 43. Baxter NT, Schmidt AW, Venkataraman A, et al. Dynamics of human gut microbiota and
- short-chain fatty acids in response to dietary interventions with three fermentable fibers.
- 508 *mBio* 2019;10(1):e02566-18.
- 509 44. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical
- 510 review. *Tuberculosis* 2011;91(6):497-509.
- 45. Light RW. Update on tuberculous pleural effusion. *Respirology* 2010;15(3):451-58.
- 46. Thornton CS, Mellett M, Jarand J, et al. The respiratory microbiome and nontuberculous
- 513 mycobacteria: an emerging concern in human health. European Respiratory Review
- 514 2021;30(160)

- 47. Wilson D, Badri M, Maartens G. Performance of serum C-reactive protein as a screening
- test for smear-negative tuberculosis in an ambulatory high HIV prevalence population.
- 517 PLoS ONE 2011;6(1):e15248.
- 518 48. Sage E, Noursadeghi M, Evans H, et al. Prognostic value of C-reactive protein in HIV-
- 519 infected patients with Pneumocystis jirovecii pneumonia. International journal of STD &
- 520 *AIDS* 2010;21(4):288-92.
- 49. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher levels of CRP, D-dimer, IL-6, and
- 522 hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with
- 523 increased risk of AIDS or death. *Journal of Infectious Diseases* 2011;203(11):1637-46.
- 524 50. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum C-
- reactive protein for screening for HIV-associated tuberculosis. The International journal of
- 526 tuberculosis and lung disease 2013;17(5):636-43.
- 527 51. Ciccacci F, Floridia M, Bernardini R, et al. Plasma levels of CRP, neopterin and IP-10 in
- 528 HIV-infected individuals with and without pulmonary tuberculosis. Journal of Clinical
- Tuberculosis and Other Mycobacterial Diseases 2019;16:100107.
- 530 52. Liu H, Zheng R, Wang P, et al. IL-37 confers protection against mycobacterial infection
- 531 involving suppressing inflammation and modulating T cell activation. PLoS ONE
- 532 2017;12(1):e0169922.
- 53. Steingart KR, Schiller I, Horne DJ, et al. Xpert® MTB/RIF assay for pulmonary
- 534 tuberculosis and rifampicin resistance in adults. Cochrane database of systematic
- 535 reviews 2014(1)
- 536 54. Yoon C, Semitala FC, Atuhumuza E, et al. Point-of-care C-reactive protein-based
- tuberculosis screening for people living with HIV: a diagnostic accuracy study. The Lancet
- 538 Infectious Diseases 2017;17(12):1285-92.
- 539 55. Rogers GB, Zain NMM, Bruce KD, et al. A novel microbiota stratification system predicts
- 540 future exacerbations in bronchiectasis. Annals of the American Thoracic Society
- 541 2014;11(4):496-503.

56. Richardson H, Dicker AJ, Barclay H, Chalmers JD. The microbiome in bronchiectasis.
 European Respiratory Review 2019;28(153)

Data availability
Data and code will be made available upon publication. Other supporting data are available from the corresponding author (GT) on reasonable request.

Table 1: Demographic and clinical characteristics of people with presumptive TB pericarditis. dTBs were more likely to have HIV, cough, weigh less, be using non-TB medications and, in PF, have lower albumin concentrations and higher ADA, LDH, and uIFN-γ concentrations than nTBs. pTBs were more likely to have HIV, previous TB, more self-reported symptoms, have lower albumin concentration, and have higher ADA and uIFN-γ fluid concentration, than nTBs. dTBs were less likely to already be on treatment at recruitment (< 2 weeks) compared to pTBs. Data are n/N (%) or median (IQR).

	Pe	ople with pres	p-value				
	Total (n=139)	dTB (n=91)	pTB (n=25)	nTB (n=23)	dTB vs. pTB	dTB vs. nTB	pTB vs. nTB
Age, years	37 (31, 48)	40 (31, 48)	34 (31, 46)	37 (31, 58)	0.910	0.563	0.485
Sex (Female)	59/139 (42)	37/91 (41)	10/25 (40)	12/23 (52)	>0.999	0.450	0.580
Current tobacco smoker	30/138 (22)	17/90 (19)	6/25 (24)	7/23 (30)	0.780	0.360	0.860
Previous tobacco smoker	29/108 (27)	19/73 (26)	7/19 (37)	3/16 (19)	0.370	0.950	0.420
Clinical characteristics:							
HIV	75/139 (54)	53/91 (58)	20/25 (80)	2/23 (9)	0.046	<0.0001	<0.0001
On ART	26/73 (37)	18/53 (34)	7/18 (39)	1/2 (50)	0.930	>0.999	>0.999
CD4 count, cells/µl	158 (54, 319)	151 (49, 328) 208 (97, 339		106 (36, 176)	>0.999	>0.999	0.971
Previous TB	31/136 (23)	21/88 (24)	9/25 (36)	1/23 (4)	0.339	0.072	0.019
Self-reported symptoms:							
Cough	76/132 (58)	52/85 (61)	16/24 (67)	8/23 (35)	0.801	0.043	0.058
Fever	52/131 (40)	35/85 (41)	12/23 (52)	5/23 (22)	0.480	0.142	0.067
Night sweats	68/133 (51)	45/86 (52)	15/24 (63)	8/23 (35)	0.510	0.210	0.110
Weight loss	85/134 (63)	60/87 (69) 17/24 (71)		8/23 (35)	>0.999	0.006	0.029
Chest X-ray results:							
Cardiomegaly	93/139 (67)	61/91 (67)	17/25 (68)	15/23 (65)	>0.999	>0.999	>0.999
Pulmonary infiltrates	31/139 (22)	23/91 (25)	4/25 (16)	4/23 (17)	0.480	0.600	>0.999
Hilar lymphadenopathy	11/139 (8)	7/91 (8)	2/25 (8)	2/23 (9)	>0.999	>0.999	>0.999
Miliary pattern	7/139 (5)	6/91 (7)	1/25 (4)	0/23 (0)	0.990	0.460	>0.999
Pleural effusion	88/139 (63)	60/91 (66)	16/25 (64)	12/23 (52)	>0.999	0.330	0.590
Pericardial tamponade	47/127 (37)	29/81 (36)	9/23 (39)	9/23 (39)	0.960	0.960	>0.999
Treatment history:							
Current TB treatment (<2 weeks)	21/139 (15)	12/91 (13)	9/25 (36)	0/23 (0)	0.020	0.144	0.005
No TB treatment	118/139 (85)	79/91 (87)	16/25 (64)	23/23 (100)	0.020	0.144	0.005
Other medications	58/129 (45)	33/83 (40)	9/23 (39) 16/23 (70)		>0.999	0.210	0.076
Non-TB antibiotic use within 1 year	21/125 (17)	12/80 (15)	7/24 (29)	2/17 (12)	0.200	>0.999	0.350
Current non-TB antibiotic use	17/21 (81)	10/12 (83)	5/7 (71)	2/2 (100)	0.980	>0.999	>0.999
Total volume aspirated (mL)	otal volume aspirated (mL) 700 (500, 1000)		720 (500, 1000)	750 (400, 1050)	>0.999	>0.999	>0.999
Fluid cytochemistry:							
ADA (U/L)	48 (26, 67)	51 (34, 68)	50 (38, 65)	16 (11, 33)	>0.999	0.001	0.016
Protein (g/L)	58 (50, 65)	58 (49, 64)	61 (55, 67)	60 (50, 64)	>0.999	>0.999	>0.999
LDH (g/L)	696 (424, 1440)	840 (451, 1440)	645 (541, 1490)	408 (181, 842)	>0.999	0.016	0.132

	Albumin (U/L)	22 (16, 26)	21 (16, 25)	23 (19, 26)	28 (25, 30)	>0.999	0.010	0.126
	uIFN-γ (pg/mL)	803 (3, 2510)	10) 1150 (165, 2590) 885 (28 (0, 5)	>0.999 <0.0001		<0.0001
	Blood CRP (mg/L)*	125 (71, 177)	137 (75, 176)	136 (93, 202)	96 (45, 174)	>0.999	>0.999	>0.999
	Mortality	24 (18)	14/88 (16)	4/24 (17)	6/22 (27)	>0.999	0.350	0.610
5	56 *For CRP, paired samples w	ere available from	112/139 parti	cipants (72/91	dTB; 20/25	pTB and 20	/23 nTB). N	lissing data

*For CRP, paired samples were available from 112/139 participants (72/91 dTB; 20/25 pTB and 20/23 nTB). Missing data: Current tobacco smoker (n=1), Previous tobacco smoker (n=31), ART status (n=2), Previous TB (n=3), Self-reported symptoms (n=8), Other medications (n=10), Non-TB antibiotic use within 1 year (n=14). Bold indicates statistical significance (P < 0.05). Abbreviations: ADA: adenosine deaminase; ART: antiretroviral therapy; CRP: C-reactive protein; dTB: definite tuberculous pericarditis; IQR: interquartile range; LDH: lactate dehydrogenase; nTB: non-tuberculous pericarditis; pTB: probable tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis; and uIFN-γ: unstimulated interferon gamma

Table 2: CRP levels do not affect microbiome α -diversity, but influence β -diversity in people with presumptive TBP. α -diversity remained consistent regardless of CRP concentration, while significant differences in β -diversity were observed, indicating distinct microbial compositions between the two groups.

	Overall (n=139)		dTB (n=91)			pTB (n=25)			nTB (n=23)			
High vs. low CRP		β-diversity			β-diversity			β-diversity			β-diversity	
		p- value	R² value	α-diversity	p-value	R² value	α-diversity	p-value	R² value	α-diversity	p-value	R ² value
All participants	0.982	0.015	0.02723	0.982	0.013	0.02723	0.2265	0.527	0.0461	0.5967	0.3333	0.04407
Within HIV-positives	0.8932	0.059	0.02537	0.5028	0.05	0.03891	0.6744	0.826	0.04857	0.3173	-	-
Within HIV-negatives	0.1432	0.526	0.01987	0.2282	0.719	0.03419	0.1213	0.3333	0.36901	0.6911	0.668	0.04903

Bold indicates statistical significance (P < 0.05). Abbreviations: CRP: C-reactive protein; dTB: definite tuberculous pericarditis; nTB: non-tuberculous pericarditis; pTB: probable tuberculous pericarditis; TB: tuberculosis.

Figure legends

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

Figure 1: Study flow chart. Pericardial fluid, skin and background controls were collected from 140 presumptive TBP people. dTBs: definite tuberculous pericarditis; nTBs: nontuberculous pericarditis; pTBs: probable tuberculous pericarditis; Smear: Smear microscopy; MGIT960 Culture: Mycobacteria Growth Indicator Tube 960 liquid culture; Xpert: Xpert MTB/RIF; Ultra: Xpert MTB/RIF Ultra. Figure 2: dTBs have a distinct microbiome enriched in Mycobacterium and other potential opportunistic pathogens. (A) Although α-diversity, which measures species diversity, was similar across the three groups, (B) β-diversity, which measures differences in microbial composition, differed significantly between PF microbiota of pTBs vs. dTBs and pTBs vs. nTBs. (C) dTBs vs. nTBs were Mycobacterium-, Lacticigenium- and Kocuriaenriched, and Streptococcus-depleted. (D) dTBs vs. pTBs were Mycobacterium-, Lacticigenium-, and Caulobacter-enriched and Streptococcus-depleted. (E) pTBs vs. nTBs were Novosphingobium- and Streptococcus-enriched (red dotted line represents adjusted pvalue=0.2; circle size represents relative abundance; taxa identified as possible contaminants are shown in grey). (F) Genus-level average relative abundances of top taxa differentiating between TB groups. dTB: definite tuberculous pericarditis; nTB: nontuberculous pericarditis; PF: pericardial fluid; pTB: probable tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis. Figure 3: Bifidobacterium enrichment is associated with Mycobacterium and HIV positivity in TBP. In PLHIV, (A) α-diversity did not differ by TB status, (B) however, βdiversity did, (C) where HIV-positive dTBs were Mycobacterium-, Bifidobacterium-, and Leptothrix-enriched, and Streptococcus-depleted compared to HIV-positive pTBs. In people without HIV, both (D) α-diversity and (F) β-diversity did not differ by TB status, and HIV-

negative dTBs were Mycobacterium, Caulobacter, and Weeksella-enriched, and

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618


619

620

Streptococcus-depleted compared to HIV-negative pTBs (red dotted line represents adjusted p-value=0.2; circle size represents relative abundance; taxa identified as possible contaminants are shown in grey). dTB: definite tuberculous pericarditis; HIV+: HIV-positive; HIV-: HIV-negative; nTB: non- tuberculous pericarditis; PF: pericardial fluid; pTB: probable tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis Figure 4: Correlations between imaging and clinical characteristics and the PF microbiota. Pulmonary infiltrates (PI) and pleural effusions (PE) are assotiated with PF microbiome. Compared to patients without PI, (A) presumptive TBPs with a PI were Mycobacterium-enriched and Lacticigenium- and Streptococcus-depleted, whilst (B) compared to patients without PE, presumptive TBP people with PE were Streptococcus- and Pseudomonas-enriched, and Brachymonas-depleted (red dotted line represents adjusted pvalue=0.2; circle size represents relative abundance; taxa identified as possible contaminants are shown in grey). dTB: definite tuberculous pericarditis; PF: pericardial fluid; PE: pleural effusions; PI: pulmonary infiltrates; pTB: probable tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis Figure 5: Inferred functional content shows enrichment of SCFA metabolic pathways in the PF of TBP. PF in dTBs infer a disctint functional capacity, including an enrichment of pathways associated with the production of short-chain fatty acids (SCFAs), aromatic compound degradation, and mycobacterial metabolism vs. nTBs (red dotted line represents adjusted p-value=0.05; circle size represents relative abundance; pathways of interest are bolded). dTB: definite tuberculous pericarditis; PF: pericardial fluid; nTB: non-tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis; SCFA: short chain fatty acids. Figure 6: Microbial composition differs in presumptive TBP people with high vs low CRP.

A) CRP levels are similar in dTBs vs. pTBs vs. nTBs. B) Mycobacterial reads do not correlate with CRP levels; r_s represents the Spearman's Rho coefficient for the correlation of mycobacterial reads with CRP. People with high CRP levels have similar C) *Mycobacterium* reads and D) α-diversity in their pericardial fluid compared to people with low CRP levels (solid circles: dTB; empty squares: pTB; empty circles: nTB). E) β-diversity differs between people with high vs low CRP. F) *Pseudomonas* is depleted in people with high vs low CRP. Discriminatory taxa appear above the threshold (red dotted line, FDR=0.2); circle size represents relative abundance. CI, Confidence interval; CRP, C-reactive protein; dTB: definite-TBP; FDR, false discovery rate; nTBP, non-TBP; PERMANOVA, permutational multivariate analysis of variance; pTB: probable-TBP; TBP: tuberculous pericarditis.

Figure 1.



Samples from 140 people were randomly rarefied to a depth of 1821 features and one sample with insufficient depth was excluded, leaving samples from 139 people.

Abbreviations: ART: antiretroviral therapy; dTB: definite tuberculous pericarditis; MGIT960 culture: mycobacteria growth indicator tube 960 liquid culture; nTB: non-tuberculous pericarditis; pTB: probable tuberculous pericarditis; Smear: Smear microscopy; Ultra: Xpert MTB/RIF Ultra; Xpert: Xpert MTB/RIF; TB: tuberculous; TBP: tuberculous pericarditis.

Figure 2.




Figure 3.





Figure 4.

Chest X-ray abnormalities



Effect size: log2(fold-change)

Figure 5.




Figure 6.

